Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14376 - 14400 of 14602 in total
Iguratimod is under investigation in Rheumatoid Arthritis.
Investigational
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and
Experimental
Illicit
Experimental
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and
Imiglitazar has been used in trials studying the treatment of Diabetes Mellitus.
Investigational
MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational
Roxarsone is an organoarsenic molecule added to poultry feed. The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent the growth of coccidian parasites. The drug is also approved in the United States for use in pigs.
Vet approved
Matched Description: … The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent …
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages …
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and
Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Investigational
Displaying drugs 14376 - 14400 of 14602 in total